Haleon (NYSE:HLN) Shares Gap Down – What’s Next?

Haleon PLC Sponsored ADR (NYSE:HLN) shares gapped down prior to trading on Wednesday . The stock had previously closed at $9.47, but opened at $9.09. Haleon shares last traded at $9.2250, with a volume of 3,272,993 shares traded.

Analysts Set New Price Targets

Several equities analysts have commented on HLN shares. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Argus upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

Haleon Price Performance

The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $41.22 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 1.97 and a beta of 0.26. The firm’s 50 day simple moving average is $10.05 and its 200 day simple moving average is $9.97.

Haleon (NYSE:HLN) last released its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The firm had revenue of $3.65 billion during the quarter. As a group, research analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be issued a dividend of $0.1307 per share. The ex-dividend date is Friday, April 10th. This represents a yield of 266.0%. Haleon’s payout ratio is presently 64.10%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC grew its stake in Haleon by 7.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 102,062 shares of the company’s stock worth $1,018,000 after acquiring an additional 7,105 shares in the last quarter. Personal CFO Solutions LLC increased its holdings in Haleon by 11.5% during the 1st quarter. Personal CFO Solutions LLC now owns 15,673 shares of the company’s stock worth $157,000 after purchasing an additional 1,620 shares during the period. Resonant Capital Advisors LLC raised its position in Haleon by 20.5% during the 1st quarter. Resonant Capital Advisors LLC now owns 31,874 shares of the company’s stock valued at $319,000 after purchasing an additional 5,428 shares in the last quarter. Abel Hall LLC bought a new stake in Haleon during the 1st quarter valued at $119,000. Finally, QRG Capital Management Inc. lifted its holdings in shares of Haleon by 17.4% in the 1st quarter. QRG Capital Management Inc. now owns 379,517 shares of the company’s stock worth $3,799,000 after buying an additional 56,362 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.